Navigation Links
Despite efforts, significant racial disparities in cancer therapy still exist
Date:1/7/2008

Black patients are significantly less likely than their white counterparts to receive therapy for various kinds of cancer, despite recent efforts to close gaps in treatment, according to a study by researchers at Yale School of Medicine published in the January 7 online issue of the journal Cancer.

Prior research revealed racial disparities in cancer care in the early 1990s. Cary P. Gross, M.D., associate professor of medicine at Yale School of Medicine, and colleagues studied the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to evaluate whether greater attention and investment in access to care for all individuals have led to any reduction in cancer treatment disparities. They evaluated patients in the SEER database who had been diagnosed with breast, colorectal, lung or prostate cancer between 1992 and 2002.

After identifying therapies for which racial disparities had been previously reported, the investigators determined whether there had been any changes in care for the overall Medicare population or for white and black patients considered separately. The team evaluated 7,775 colon, 1,745 rectal, 11,207 lung, 40,457 breast and 82,238 prostate cancer cases.

The team found that throughout the study period, black patients were significantly less likely than white patients to receive therapy for cancers of the lung, breast, colon and prostate. For both black and white patients, there were little or no improvements in the proportion of patients receiving therapy for most cancers. There was also no decrease in the magnitude of racial disparities between 1992 and 2002. These racial disparities persisted even after limiting the analysis to patients who had access to a physician prior to their cancer diagnosis.

The findings suggest that there has been little improvement in the overall proportion of Medicare beneficiaries receiving cancer care. They also reveal that racial disparities have not les
'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Coshocton County Memorial Hospital RNs to Strike Despite Hospitals Claim of Financial Hardship
2. Miscarriage myths persist despite prevalence of medical information
3. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. A Full and Long Life, Despite Diabetes
6. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
7. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
8. UGA study: Youth exposed to smokeless tobacco ads despite settlement
9. Cataract Surgery: A Bargain, Despite the Price
10. Most patients who have male-to-female sex-change surgery are happy, despite complications
11. Despite grumbling, most Americans say they are happy at work

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Despite efforts, significant racial disparities in cancer therapy still exist
Despite efforts, significant racial disparities in cancer therapy still exist
(Date:11/9/2009)...MENTO, Calif., Nov. 9 Sutter Healt...nd other health care service providers, is donatin...a. A variety of local food banks will share the qu...ded meals on the tables of thousands of families a... long history of partnering with and supporting ch...
(Date:11/9/2009)...NGELES, Nov. 9 Tracy Anderson, tra... Kate Hudson, will be hosting two events at her LA...nally sharing her long awaited Nutritional Meal Pl... her TA Baby Food Cleanse and Lifestyle Menu. She...rates her entire method of cardio and muscle struc...
(Date:11/9/2009)... Studying Genetic Variance Across th...f Genes , (Vocus) Novembe...ies can be extraordinarily valuable when analyzing...enter genetics study that scanned the genomes of...gional differences, Drs. Chao Tian and Michael F. ...
(Date:11/9/2009)...of plans finds differences in mood despite similar...ay News) -- Both a high-fat, low-carbohydrate diet... high-carb diet appear to help people lose pounds ...Only the low-fat diets will result in long-term im.... 9 issue of Archives of Internal Medicine . ,...
(Date:11/9/2009)... Fast food chains are often blamed f...cent poll by Fitness.com.au however finds that 80%...responsibility. , (PRWEB)...ns, and video games were behind Australia’s ...re than just innocent bystanders. A recent survey ...
Breaking Medicine News(10 mins):Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2Health News:Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week 2Health News:News from the November/December Issue of Molecular Medicine 2Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2
...Feb. 25 Zimmer Holdings, Inc. (NYSE: ZMH ; SWX:... announced that an interactive Trabecular Metal (...ghts of the Company,s presence at the 76th annual ...an the Company,s portfolio, and The Zimmer Institu...
...25 The University of Texas M. D. Anderson Cance...l Gamma Knife (R) Perfexion(TM), an advanced rad...ne or more lesions in the head in a single session...its our clinical needs," says Eric Chang, M.D., Di...
...aldrige National Quality Award Recipient & Mag...ractices for Leveraging Patient Engagement to Impr...25 GetConnected2009, the second annual users conf...ors and administrators from leading hospitals and ...
...ina, Feb. 25 /PRNewswire-Asia-FirstCall/ -- China ..."the Company") (Nasdaq: CSKI ), a,leading fully ...he-counter drugs in the People,s Republic of China...mei Slim Patch into,South Korea and Sudan. As a re...
...LLE, N.J., Feb. 25 Aton Pharma, Inc., a,diversifi...ed it has acquired,the U.S. marketing rights to th...c. TIMOPTIC (timolol maleate) is a non-selective b... glaucoma. As many as 2.25,million Americans suffe...
..., Feb. 25 Already a leader in the High Tech ind...Intelligence software, is now offering its anti-co... , , Stu Clifton, New Momentum CEO, reported, "...he pace of legitimate pharmaceuticals -- and could...
Other Medicine News:Health News:Zimmer Presents Trabecular Metal Technology Experience at AAOS Annual Meeting 2Health News:Zimmer Presents Trabecular Metal Technology Experience at AAOS Annual Meeting 3Health News:Zimmer Presents Trabecular Metal Technology Experience at AAOS Annual Meeting 4Health News:Zimmer Presents Trabecular Metal Technology Experience at AAOS Annual Meeting 5Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:GetWellNetwork Announces GetConnected2009 2Health News:GetWellNetwork Announces GetConnected2009 3Health News:China Sky One Medical, Inc. Exports Sumei Slim Patch to South Korea and Sudan 2Health News:China Sky One Medical, Inc. Exports Sumei Slim Patch to South Korea and Sudan 3Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3Health News:New Momentum Launches Anti-Counterfeiting Software for Pharmaceutical Companies 2
(Date:11/10/2009)...ass. and TOKYO, Nov. 10 Ironwood P...y announced that they have entered into an agreeme...and commercialize the investigational compound lin...es, Taiwan, and Thailand. Linaclotide is currently...tes for the treatment of irritable bowel syndrome ...
(Date:11/9/2009)...Ala., Nov. 9 Surgical Ca... host an investor conference call at 11:00 a.m. Ea...s its 2009 third quarter operating results. A 30-... following the conclusion of the conference call. ...h/20080812/CLTU111LOGO ) ,, Please go to SCA...
(Date:11/9/2009)...s., Nov. 9 Hologic, Inc....ing developer, manufacturer and supplier of premiu...l products dedicated to serving the healthcare nee...ourth quarter and fiscal year ended September 26, ...rd of Directors has promoted Robert Cascella to Ch...
Breaking Medicine Technology:Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 2Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 2Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 4Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 5Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 6Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 7Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 8Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 9Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 10Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 11Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 12Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 13Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 14Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 15Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 16Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 17Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 18Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 19Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 20Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 21Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 22Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 23Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 24Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 25Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 26Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 27Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 28VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 1VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 5nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 1nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 2nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 3nCircle and HITRUST Partner to Deliver Innovative SaaS Offering to Secure Healthcare Information 48586 4ReStart DC Launches Life Saving Public Access Defibrillation Program 48583 1ReStart DC Launches Life Saving Public Access Defibrillation Program 48583 2ReStart DC Launches Life Saving Public Access Defibrillation Program 48583 3
... 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq:ACAD) ... Phase II schizophrenia co-therapy trial with ACP-...erse agonist. The trial,evaluated ACP-103 co-thera...ommonly prescribed atypical antipsychotic drug, or.... The co-therapy,arms with ACP-103 demonstrated st...
...ire-FirstCall/ -- La Jolla,Pharmaceutical Company ... data for the Phase 3 trial of Riquent(R) (abetimu...rythematosus,("lupus" or "SLE"). The updated analy...s a definitive and significant dose response,betwe...compared,with placebo (p=0.0001). These interim da...
Other Medicine Technology:Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 2Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 3Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 4Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 5Acadia Announces Positive Results From ACP-103 Phase II,Schizophrenia Co-Therapy Trial 6La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6
MG-1000
...R offers a broad range of applications. Many funct...ration. For the height adjustment, the table is eq...to its uncomplicated handling, MERKUR can be used ...le manner. Furthermore, a comprehensive range of a...
MAQUET Orthostar II
...artner when radiological examinations or intervent... an intervention. Due to the motorised longitudina...Enduro provides optimum working conditions in exam...l coupling points ensure that the table can be ext...
Medicine Products: